Addex Therapeutics (ADXN) Cost of Revenue (2021 - 2025)

Addex Therapeutics has reported Cost of Revenue for 4 years, with the latest figure at $4856.9 in Q2 2025.

• Quarterly Cost of Revenue changed N/A year-over-year to $4856.9 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $322362.9 (changed N/A YoY) and the FY2024 annual result came in at $20159.4, down 94.6% from the prior year.
• Cost of Revenue slipped to $4856.9 in Q2 2025 per ADXN's latest filing, from $121395.1 in the prior quarter.
• Over five years, Cost of Revenue peaked at $121395.1 in Q2 2023 and troughed at $4856.9 in Q2 2025.
• A 4-year average of $80590.7 and a median of $98055.4 in 2021 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue rose 14.56% in 2022, then gained 15.93% in 2023.
• Over 4 years, Cost of Revenue stood at $91400.1 in 2021, then grew by 14.56% to $104710.8 in 2022, then climbed by 15.93% to $121395.1 in 2023, then plunged by 96.0% to $4856.9 in 2025.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4856.9, $121395.1, and $104710.8 for Q2 2025, Q2 2023, and Q2 2022 respectively.